ZyCoV-D is a three-dose vaccine administered intradermally.
Global private equity investor Advent International on Monday said it is acquiring a significant stake in Suven Pharmaceuticals from its promoters, the Jasti family. The PE major said this will be followed with an open offer to acquire 26 per cent more in the listed contract development and manufacturing organisation from public shareholders, and also merge the company with investee company Cohance Lifesciences, as per an official statement. Media reports on a Monday morning pegged the acquisition at Rs 6,300 crore, and that Advent had pipped rival Blackstone for the acquisition.
The primary market is set for a bumper Rs 80,000-crore bonanza with 30 companies already filing IPO papers to raise Rs 55,000 crore, while around 10 more are lined up for this month itself, seeking to mop up another Rs 25,000 crore, say investment bankers. The market has been on a non-stop rally, hitting new records almost every week, on the back of an influx of investors -- a vast majority of them first-timers -- coupled with a flood of liquidity. Foreign funds alone had pumped in a record $35 billion into the market in FY21, while the trend has continued this fiscal as well. Domestic institutions led by LIC have also infused trillions of rupees, helping woo retail investors in troves -- the year saw over 20 million new investors coming to the market.
India's top vaccinologist Gagandeep Kang stressed the need to develop better vaccines that can deal with new variants, and strengthening of the regulatory mechanisms.
'Just put a patch on your arm and the vaccine can be absorbed by the body.'
Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. There are two kinds of testing for the novel coronavirus - the real-time polymerase chain reaction test kit that uses throat or nasal swabs and provides results in a few hours, and the other is antibody-based rapid testing kit that use blood samples and provides results in a few minutes.
Indian drug firms get a shot in the arm in the $12 bn Australian drug market as the Therapeutic Goods Administration (TGA), Australia agrees to accelerate the drug approval process in that country for Indian players who already have an approved plant and product from one of the stringent regulatory authorities like US, EU or Canada. From current sales of $340 mn, the Indian firms can see a significant upside in sales; felt Dinesh Dua, former chairman of the Pharmaceutical Exports Promotion Council of India (Pharmexcil), and the MD of Nectar Lifesciences. He highlighted that only 12 percent of the Australian drug market is generic, as against 80-90 per cent in the US or EU. Of this $1.5 bn generic drug market in India, Indian companies have a small share.
Former actress Mamta Kulkarni was on Saturday named as a prime accused in a multi-crore drug racket linked to drug baron Vicky Goswami, with Mumbai police claiming that she was actively involved in the illicit activities and would seek her extradition from Kenya.
Chafing is an unpleasant reality that many people ignore, and it can truly mess up your lifestyle.
The Ahmedabad-based Claris Lifesciences has received the United States Food & Drug Administration clearance for its sterile injectable manufacturing facility near Ahmedabad.
Since the beginning of 2020, i-bankers have collected nearly Rs 1,800 crore by way of IPO fees. Interestingly, the India fees this year form just 1 per cent of the global fee pool of $13.7 billion from IPOs.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Companies featuring in the Next 500 list are mostly mid-sized and termed as the 'small wonders' by the magazine.
The price band for the Rs 90 crore (Rs 900 million) initial public offer of Chandigarh-based Nectar Lifesciences has been fixed at Rs 200-Rs 240 per equity share of Rs 10 each.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Agriculture activity, according to recent channel checks by Prabhudas Lilladher, is expected to continue at a strong pace in FY22.
Hectic fundraising through initial public offerings (IPOs) is expected in October-November, with at least 30 companies are looking to collectively raise over Rs 45,000 crore through initial share-sales, merchant banking sources said. Of the total fundraising, a large chunk would be garnered by technology-driven companies. The successful IPO of food delivery company Zomato, which was overwhelmingly subscribed by over 38 times, encouraged new-age tech companies to come out with their primary share-sales.
First day of the sixth edition of 'Vibrant Gujarat' saw investment commitments of Rs 28,000 crore from corporates such as Essar, ABG Shipyard, Jubilant Lifescience and Adanis.
Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, a Department of Information Technology (Government of India) Center of Excellence for Research and Training in Bioinformatics, invites applications.
Nidhi Saxena, founder of Karmic Lifesciences, a contract research organisation that was born in the bleak days of mid-2008, reveals what made her venture a success in four years.
Ranbaxy, which ranks second in domestic sales among drug companies (it is the largest in total sales), has announced plans to be the market leader in the next few years.
Under the new model, the IT services firm will replace the current structure of its various strategic business units, service lines and geographies with four strategic market units and two global business lines.
Ranbaxy Laboratories on Tuesday said it will acquire Bangalore-based Biovel Lifesciences for an undisclosed amount.
The county's largest IT company TCS on Friday reported a 7.2 per cent jump in December quarter net to Rs 8,701 crore on a consolidated basis, and seemed to suggest the worst is behind by projecting double-digit revenue growth for FY22. The company, a cash cow for Tata Sons, saw a 5.4 per cent growth in revenue at Rs 42,015 crore for the quarter. Operating profit margin came in at 26.6 per cent despite implementing wage hikes, after consistently missing the 26-28 per cent aspirational band for many quarters.
Last year the company had acquired four companies, including one in the telecom sector, and plans to do the same in the coming months.
The company's total income was up 2.2 per cent to Rs 13,480 crore in the quarter under review from Rs 13,183 crore in the corresponding quarter last year
Arysta, the target, is a leading crop protection and life sciences firm.
VHB Lifesciences Inc, a pharmaceutical company, is looking for Institutional Managers.
'We have to plan for whatever the new normal is.'
Venky's India is a contrarian pick in the poultry industry
Suven Life Sciences Ltd has signed an agreement with US-based pharmaceutical firm Eli Lilly and Company to carryout pre-clinical research for central nervous system disorder.
Jhunjhunwala increases stake in DHFL, luggage maker VIP Industries and pharma major Lupin but is cautious on auto holding. At the end of the March quarter, Jhunjhunwala held positions in 29 firms.
Thirty-two IPOs that have hit the capital market in the first 10 months of calendar year 2005 have collectively seen an erosion of market value worth Rs 3,682 crore after their listing on the bourses.
GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances